Functional High Throughput Drug Screening Reveals Cyproheptadine as a Novel Treatment for LMNA -related Cardiomyopathy
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objectives
To define shared and variant-specific mechanisms underlying LMNA-associated dilated cardiomyopathy (DCM) and identify therapeutic candidates using human stem cell–based models.
Background
Variants in the gene LMNA, encoding lamin A/C, cause 5–10% of dilated cardiomyopathies (DCM) and are strongly associated with heart failure and arrhythmias. Yet, the mechanisms by which LMNA variants drive disease and the distinction between shared and variant-specific phenotypes remain unclear.
Methods
To address this, we generated human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from six LMNA-DCM patients carrying three pathogenic variants (T150A, E381Afs*39, R527H) and from five healthy control patients.
Results
LMNA hiPSC-CMs exhibited nuclear membrane deformation, reduced beat rate, arrhythmias, and prolonged calcium transients. Transcriptomic and electrophysiological analyses revealed downregulation of cardiac genes and ion channels, with abnormal Ca²⁺ handling emerging as a shared disease mechanism. Leveraging a high-throughput functional assay, we performed an unbiased drug screen and identified cyproheptadine, an FDA-approved antihistamine, as the only compound to alleviate abnormal function across all LMNA variants.
Conclusion
Our findings reveal a shared disease mechanism across multiple LMNA variants driven by dysregulated Ca²⁺ handling. This work establishes a patient-specific drug discovery platform and identifies cyproheptadine as a promising therapeutic candidate for LMNA-associated dilated cardiomyopathy.
Highlights
-
Patient-specific LMNA hiPSC-cardiomyocytes robustly recapitulate disease phenotypes, including nuclear defects, arrhythmias, and contractile dysfunction.
-
Dysregulated calcium handling emerges as a unifying mechanism driving pathology across distinct LMNA variants.
-
Variant-resolved analysis reveals both shared and mutation-specific molecular and functional signatures.
-
High-throughput screening identifies cyproheptadine as a potent, broadly effective rescue agent across all tested LMNA variants.
-
This work establishes a scalable precision medicine platform for rapid therapeutic discovery in inherited cardiomyopathies.
